Evidence map›Paper›PMID 41658964›Full record

ReviewInternational journal of cardiology. Cardiovascular risk and prevention2026

Colchicine therapy in transcatheter aortic valve replacement: Modulating inflammation and outcomes.

Hamza A Abdul-Hafez, Ameer Awashra, Malik Ahmad, Abdullah Raed Hawawrah, Bayan Mahafdah, Mohammed AbuBaha, Ibrahim Alazizi, Abdalhakim Shubietah, Mohamed S Elgendy, Ahmed Emara

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hamza A Abdul-HafezDepartment of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Ameer AwashraDepartment of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Malik AhmadDepartment of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Abdullah Raed HawawrahDepartment of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Bayan MahafdahFaculty of Medicine, Yarmouk University, Irbid, Jordan.
Mohammed AbuBahaDepartment of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Ibrahim AlaziziDepartment of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Abdalhakim ShubietahDepartment of Medicine, Advocate Illinois Medical Center, Chicago, IL, USA.
Mohamed S ElgendyFaculty of Medicine, Tanta University, Tanta, Egypt.
Ahmed EmaraFaculty of Medicine, Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Transcatheter aortic valve replacement (TAVR) is frequently accompanied by inflammation-related complications, including conduction disturbances, atrial fibrillation, and subclinical leaflet thrombosis. Colchicine, with its anti-inflammatory and antithrombotic properties, has emerged as a potential adjunctive therapy to mitigate these post-procedural events. However, its specific role in the TAVR population remains insufficiently defined. Methods: A narrative review approach was used. Searches of PubMed, Scopus, Web of Science, and Google Scholar were performed through September 2025 using terms related to "transcatheter aortic valve replacement," "TAVR," and "colchicine." Randomized trials, observational studies, mechanistic investigations, and guideline documents were screened. Findings were organized thematically to summarize mechanisms, therapeutic rationale, and clinical outcomes. Results: Only one randomized controlled trial and one observational study have directly evaluated colchicine after TAVR. Both demonstrated reductions in inflammatory biomarkers and signals toward improved conduction-related parameters, but clinical endpoints such as pacemaker implantation, sustained arrhythmias, and imaging-confirmed leaflet thrombosis remain insufficiently studied. Mechanistic and perioperative cardiac evidence from non-TAVR settings supports colchicine's potential by targeting inflammasome activity, microtubule regulation, and early thrombo-inflammatory remodeling. Conclusions: Colchicine is a promising adjunctive strategy for attenuating inflammation-related complications after TAVR. Its multimodal actions align with the pathways implicated in conduction disturbances, atrial fibrillation, and leaflet thrombosis. However, current evidence is preliminary, with only two post-TAVR intervention studies available. Larger trials are needed to determine whether colchicine can translate mechanistic advantages into clinically meaningful improvements in post-TAVR outcomes.

Indexed as

Atrial fibrillationColchicineConduction disturbancesInflammationLeaflet thrombosisReviewTAVRTranscatheter aortic valve replacement

Identifiers

PMID41658964
PMCPMC12874275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.